These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36382476)

  • 41. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
    Front Immunol; 2020; 11():1173. PubMed ID: 32587591
    [No Abstract]   [Full Text] [Related]  

  • 42. The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines).
    De Giglio A; Di Federico A; Nuvola G; Deiana C; Gelsomino F
    Curr Oncol Rep; 2021 Aug; 23(11):126. PubMed ID: 34453261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.
    Canale ML; Camerini A; Casolo G; Lilli A; Bisceglia I; Parrini I; Lestuzzi C; Del Meglio J; Puccetti C; Camerini L; Amoroso D; Maurea N
    Adv Ther; 2020 Jul; 37(7):3178-3184. PubMed ID: 32436027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis.
    Mo DC; Huang JF; Luo PH; Huang SX; Wang HL
    Int Immunopharmacol; 2021 Jul; 96():107594. PubMed ID: 33798808
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.
    Remon J; Vilariño N; Reguart N
    Cancer Treat Rev; 2018 Mar; 64():21-29. PubMed ID: 29454155
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Brito ABC; Camandaroba MPG; de Lima VCC
    Thorac Cancer; 2021 Apr; 12(7):1058-1066. PubMed ID: 33586297
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions.
    Bhalla S; Doroshow DB; Hirsch FR
    Cancer J; 2020; 26(6):507-516. PubMed ID: 33298722
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ["Treatment of lung cancer with immune checkpoints inhibitors"].
    Lamkhioued M; Dupont M; Leriche P; Pérol M
    Rev Prat; 2021 Apr; 71(4):385-390. PubMed ID: 34161003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
    Remon J; Ahn MJ; Girard N; Johnson M; Kim DW; Lopes G; Pillai RN; Solomon B; Villacampa G; Zhou Q
    J Thorac Oncol; 2019 Jul; 14(7):1134-1155. PubMed ID: 31002952
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.
    Hann CL; Scherpereel A; Hellyer JA; Wakelee HA
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():543-552. PubMed ID: 31099677
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions.
    Karim S; Leighl N
    Future Oncol; 2016 Jan; 12(1):9-23. PubMed ID: 26631501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Treatment: Quo Vadis?
    Gargalionis AN; Papavassiliou KA; Papavassiliou AG
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928013
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
    Li S; Zhang C; Pang G; Wang P
    Front Immunol; 2020; 11():603157. PubMed ID: 33178229
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive genetic biomarkers in immune checkpoint inhibitors for non-small-cell lung cancer.
    Henriques GT; Barbieri de Souza C; Aguiar PN
    Immunotherapy; 2022 Mar; 14(4):249-257. PubMed ID: 35076285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly.
    Losanno T; Gridelli C
    Curr Oncol Rep; 2021 Aug; 23(10):119. PubMed ID: 34342732
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Yang Y; Luo H; Zheng XL; Ge H
    Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects.
    Tang S; Qin C; Hu H; Liu T; He Y; Guo H; Yan H; Zhang J; Tang S; Zhou H
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159131
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?
    Kartolo A; Robinson A; Fung AS
    Future Oncol; 2022 Feb; 18(6):635-638. PubMed ID: 35018801
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.